General MedicationsORALGeneric
ASPRUZYO SPRINKLE
RANOLAZINE
Standard Dose
500MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary
Approval overview ASPRUZYO SPRINKLE is listed in Drugs@FDA under application 216018 (NDA).
Review priority: STANDARD Marketing status: Discontinued Active ingredient RANOLAZINE Form and strength GRANULES, EXTENDED RELEASE;ORAL - 500MG Sponsor SPIL Submission history Latest submission status date: 2022-02-28 00:00:00.
Structured Monograph
Clinical summary
Approval overview ASPRUZYO SPRINKLE is listed in Drugs@FDA under application 216018 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient RANOLAZINE Form and strength GRANULES, EXTENDED RELEASE;ORAL - 500MG Sponsor SPIL Submission history Latest submission status date: 2022-02-28 00:00:00. Submission type: ORIG.
Monitoring
- • Marketing status: Discontinued
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.